# Reviewer report: F3 stage-inference charts (0.2.1 pre-release build)

Reviewer: a second model (independent subagent) given only `charts.txt`, `instruction.md`, `policy.md` and `tools.md` in
this folder, and asked to decide all four candidates per patient from the CDC 2021 guidelines and the published
conventions, then list anything a competent clinician could reasonably decide differently. Its reply follows, with
its wording lightly condensed. Agreement with `answer_key.json`: **72/72**.

---

ANSWERS
```
P0ee79b0 NI, NI, NI, NI
P0f2673a NI, C, NI, NI
P18861d2 NI, NI, NI, NI
P19f19a9 C, NI, NI, NI
P1d94d5a NI, C, NI, NI
P3ea5806 NI, NI, NI, NI
P68cbfe4 NI, NI, NI, NI
P740271c C, NI, NI, NI
P7b43b8f C, NI, NI, NI
P7b6a47b NI, NI, NI, NI
P983d9c9 NI, NI, NI, NI
P9c94977 NI, NI, NI, NI
Pa82335d NI, NI, NI, NI
Pbc7f3e9 C, NI, NI, NI
Pe6039b8 C, NI, NI, NI
Pe671eb5 C, NI, NI, NI
Peaeca49 NI, C, NI, NI
Pf10a35a NI, C, NI, NI
```

General observations applying to all patients: MIS — I cross-checked all 126 results' collection records against the accessioning log; every result has exactly one accessioning entry, and MRN/DOB/accession are concordant in every case; no result is filed in another patient's chart and none are non-final, so all MIS = NI. HIV — every patient is HIV-negative, so HIV-negative follow-up schedules apply (P&S: 6, 12 mo; all latent: 6, 12, 24 mo). All required follow-up windows closed before 2026-09-24. PRG — every female had a negative serum hCG on the day of diagnosis (except Sokolov, age 54, none drawn); no later record mentions pregnancy, so all PRG = NI.

RATIONALE
- P0ee79b0 — Early latent (documented seroconversion within 12 mo: RPR NR 2024-03-07 → 1:16 w/ TP-PA+ 2024-06-14, asymptomatic). One BPG 2.4 MU 2024-06-14 = adequate. 6/12/24-mo windows due and met (2024-11-27, 2025-06-16, 2026-05-30).
- P0f2673a — Latent of unknown duration (asymptomatic, no prior test, no known contact). 3 weekly doses 3/1, 3/8, 3/15/2024 = adequate. 6-mo (2024-09-18) and 12-mo (2025-03-05) met; 24-mo due 2026-03-01 (window 2026-01-30–2026-03-31) — no RPR collected → overdue.
- P18861d2 — Early latent (RPR NR 2023-08-05 → reactive 2024-03-25, ~7.7 mo; asymptomatic). 1 dose 2024-03-25 adequate. 6/12/24 met (2024-09-18, 2025-03-30, 2026-03-16).
- P19f19a9 — Unknown-duration latent (asymptomatic, no prior testing/contact). Only 1 dose (2023-11-29); needs 3 → inadequate. 6/12/24 met (2024-06-16, 2024-12-10, 2025-12-12).
- P1d94d5a — Unknown duration (blood-donation screen, never tested, asymptomatic). 3 weekly doses 2/7, 2/14, 2/21/2024 adequate. 6-mo (2024-08-12), 12-mo (2025-01-26) met; 24-mo due 2026-02-07 (window 2026-01-08–2026-03-09) not collected → overdue.
- P3ea5806 — Secondary (22-day palm/sole rash, condylomata lata [moist perianal papules], patchy alopecia). 1 dose 2024-05-16 adequate. 6-mo (2024-11-30), 12-mo (2025-04-30) met.
- P68cbfe4 — Secondary (palm/sole rash, mucous patches, lymphadenopathy). 1 dose 2024-07-14 adequate. 6-mo (2025-01-10), 12-mo (2025-07-15) met.
- P740271c — Unknown duration. 1 dose 2024-07-29 → inadequate. 6/12/24 met (2025-02-06, 2025-07-27, 2026-07-14; last window closed 2026-08-28).
- P7b43b8f — Unknown duration (RPR 1:1, TP-PA+, no history). 1 dose 2024-06-10 → inadequate. 6/12/24 met (2024-12-19, 2025-06-23, 2026-06-03).
- P7b6a47b — Early latent (RPR NR 2023-09-04 → reactive 2024-05-23, ~8.6 mo; asymptomatic). 1 dose adequate. 6/12/24 met (2024-12-04, 2025-05-30, 2026-05-25).
- P983d9c9 — Secondary (13-day palm/sole rash, condylomata lata, alopecia). 1 dose 2024-03-26 adequate. Only 6/12 due and met (2024-09-13, 2025-03-22). Open review request answered NI — no 24-mo test recommended for HIV-negative P&S.
- P9c94977 — Secondary (papulosquamous palm/sole rash, mucous patches, generalized lymphadenopathy). 1 dose 2024-01-08 adequate. 6/12 met (2024-07-13, 2025-01-22).
- Pa82335d — Secondary (23-day palm/sole rash, mucous patches, lymphadenopathy). 1 dose 2024-05-20 adequate. 6/12 met (2024-11-08, 2025-05-14).
- Pbc7f3e9 — Unknown duration: last nonreactive screen 2022-10-17 is ~20 mo before diagnosis, so the early-latent seroconversion criterion is not met. 1 dose 2024-06-15 → inadequate. 6/12/24 met (2024-12-21, 2025-06-08, 2026-06-12).
- Pe6039b8 — Unknown duration: prior NR 2022-08-01 is ~16 mo before diagnosis (2023-12-05). 1 dose → inadequate. 6/12/24 met (2024-06-01, 2024-12-12, 2025-12-03).
- Pe671eb5 — Unknown duration: prior NR 2023-01-17 is ~15.7 mo before diagnosis (2024-05-07). 1 dose → inadequate. 6/12/24 met (2024-11-21, 2025-05-18, 2026-05-07).
- Peaeca49 — Unknown duration (no prior syphilis test; 2023-12-03 specimen was HIV only). 3 weekly doses 6/10, 6/17, 6/24/2024 adequate. 6-mo (2024-12-20), 12-mo (2025-05-31) met; 24-mo due 2026-06-10 (window 2026-05-11–2026-07-10) not collected → overdue.
- Pf10a35a — Unknown duration. 3 weekly doses 5/4, 5/11, 5/18/2024 adequate. 6-mo (2024-11-20), 12-mo (2025-05-15) met; 24-mo due 2026-05-04 (window 2026-04-04–2026-06-03) not collected → overdue.

FAIRNESS
- 24-month follow-up after seroreversion (P0f2673a, Peaeca49): both are "overdue" only for the 24-month test, but both had already become RPR-nonreactive (Farrow at 12 mo; Lindgren at 6 and 12 mo). Some clinicians would consider further serologic follow-up unnecessary once nontreponemal tests are nonreactive. CDC 2021 lists 6/12/24 months for latent syphilis without a seroreversion exception, so I answered C — but this is the most likely point of reasonable disagreement. (Not an issue for Kearney or Kenji Zimmer, whose RPR stayed at 1:1.)
- Pregnancy inferred from a single negative hCG: all PRG = NI rests on a negative hCG on the diagnosis date (none for Sokolov) and no later pregnancy documentation. Strictly the records do not prove she was not pregnant during the subsequent 2+ years, but none of the three missing-evidence codes applies and NI is the only defensible answer. Low disagreement risk.
- Early-latent staging from a prior nonreactive test: the decisive element is month-counting, not judgment. The intervals are clearly < 12 mo (~3, 7.7, 8.6 mo) or clearly > 12 mo (~15.7, 16, 20 mo); none is near the boundary. I see low ambiguity, but this is the main trap (especially Luis Petrakis at ~15.7 mo, a treated-looking chart that is actually inadequate).
- Window edges: no specimen is near enough to a window boundary to change an answer (tightest: Okonkwo 24-mo 15 days early; Tanaka 6-mo 18 days late; Kenji Zimmer 6-mo 16 days late).
- Minor oddities (not affecting answers): Dalton, Luis Petrakis and Okonkwo go from NR back to 1:1 on later follow-up (plausible one-dilution variability, but a clinician might wonder about reinfection); Alvarado has patchy alopecia with only a 13-day rash (a bit early, but staging still clearly secondary).
- Features not exercised in this set: there are no misfiled results, pending results, outside records or source conflicts, so every MIS is NI and no case needs a cannot-determine code.
- Stage leakage: no chart names a stage. The 1-dose vs 3-dose pattern reveals the treating clinician's implicit staging but does not determine the answer; the early-latent charts quote the prior nonreactive date, which is the intended clue, and the interval still has to be counted.
